Search Result

Results for "

NAD levels

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (6) CD38 (2) Endogenous Metabolite (11) HBV (3) Interleukin Related (1) IRAK (1) Isotope-Labeled Compounds (2) JAK (1) Keap1-Nrf2 (2) Mitochondrial Metabolism (3) NADH Dehydrogenase (1) NAMPT (6) Organoid (2) Oxidative Phosphorylation (1) Quinone Reductase (2) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Sigma Receptor (1) Sirtuin (10) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (21) Infection (1) Inflammation/Immunology (2) Metabolic Disease (9) Neurological Disease (8)

By Targets:

AMPK (1)

Apoptosis (6)

CD38 (2)

Endogenous Metabolite (11)

HBV (3)

Interleukin Related (1)

IRAK (1)

Isotope-Labeled Compounds (2)

JAK (1)

Keap1-Nrf2 (2)

Mitochondrial Metabolism (3)

NADH Dehydrogenase (1)

NAMPT (6)

Organoid (2)

Oxidative Phosphorylation (1)

Quinone Reductase (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

Sigma Receptor (1)

Sirtuin (10)

STAT (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (21)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (9)

Neurological Disease (8)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128895

KL1333 1 Publications Verification	Quinone Reductase Mitochondrial Metabolism	Metabolic Disease
KL1333, a derivative of β-lapachone, is an orally available *NAD+* modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .

HY-123033A

Nicotinamide riboside chloride 15+ Cited Publications	Sirtuin Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate 15+ Cited Publications	Sirtuin Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-12628

GNE-618 2 Publications Verification	NAMPT	Cancer
GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC₅₀ of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-128895A

KL1333 hydrochloride	Mitochondrial Metabolism Quinone Reductase	Metabolic Disease
KL1333 hydrochloride is an orally active NAD ⁺ modulator that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, leading to increased intracellular NAD ⁺ levels through NADH oxidation. Elevated NAD ⁺ levels trigger activation of SIRT1 and AMPK, and subsequently activate PGC-1α. KL1333 hydrochloride improves energy metabolism and mitochondrial dysfunction in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) fibroblasts. KL1333 hydrochloride protects against cisplatin-induced ototoxicity in mouse cochlear cultures .

HY-123033

Nicotinamide riboside	Sirtuin Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Sirtuin Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033D

Nicotinamide riboside (triflate)	Endogenous Metabolite Sirtuin	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside (triflate), an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside (triflate) is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside (triflate) reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-155023

Apoptosis inducer 13	Apoptosis Reactive Oxygen Species (ROS)	Cancer
Apoptosis inducer 13 (Compound Ru4) can induce cancer cell apoptosis, and inhibits cancer cell migration and invasion. Apoptosis inducer 13 converts coenzyme NADH to NAD ⁺, and increases intracellular ROS levels .

HY-10079

CHS-828 4 Publications Verification GMX1778	NAMPT Apoptosis	Cancer
CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC₅₀ less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD ⁺ and exhibits a potent anticancer activity .

HY-10079A

CHS-828 (nicotinate) GMX1778 (nicotinate)	NAMPT Apoptosis	Cancer
CHS-828 nicotinate is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC₅₀ less than 25 nM. CHS-828 nicotinate (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD ⁺ and exhibits a potent anticancer activity .

HY-123033AR

Nicotinamide riboside chloride (Standard)	Reference Standards Sirtuin Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
Nicotinamide riboside (chloride) (Standard) is the analytical standard of Nicotinamide riboside (chloride). This product is intended for research and analytical applications. Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].

HY-119648A

(E/Z)-CCR-11	CD38	Inflammation/Immunology
(E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC₅₀ of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ .

HY-117420

CM764	Sigma Receptor	Cancer
CM764 is an activator for sigma receptor with K_i of 86.6 and 3.5 nM for sigma-1 receptor and sigma-2 receptor. CM764 increases cytoplasmic calcium, NAD ⁺/NADH, and ATP levels, and decreases the concentration of ROS .

HY-156120

CD38 inhibitor 3	CD38	Metabolic Disease
CD38 inhibitor 3 (compound 1) is the orally active inhibitor for CD38 (IC₅₀=11 nM). CD38 inhibitor 3 increases intracellular NAD ⁺ levels, activates the Nrf2 signaling pathway, and promotes mitochondrial biogenesis. CD38 inhibitor 3 improves muscle function .

HY-B0150A

Nicotinamide Hydrochloride Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride	Sirtuin Endogenous Metabolite HBV	Infection Cancer
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .

HY-B0150

Nicotinamide Maximum Cited Publications 78 Publications Verification Niacinamide; Nicotinic acid amide	Organoid Endogenous Metabolite Sirtuin HBV	Cancer
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-W975966

CPDT	Keap1-Nrf2	Neurological Disease
CPDT is an orally active and highly potent inducer of phase 2 enzymes and an activator of Nrf2. The activities of key phase 2 enzymes, including glutathione S-transferase, NAD(P)H:quinone:oxidoreductase 1 and glutamate cysteine synthetase, and levels of glutathione were elevated by CPDT in rat bladder in vivo and in cultured bladder cells in vitro [2].

HY-10079R

CHS-828 (Standard) GMX1778 (Standard)	Reference Standards NAMPT Apoptosis	Cancer
CHS-828 (Standard) is the analytical standard of CHS-828. This product is intended for research and analytical applications. CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity .

HY-125147

A-1293201	NAMPT	Cancer
A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD ⁺/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .

HY-W615108B

β-Nicotinamide mononucleotide, reduced form disodium NMNH disodium	Endogenous Metabolite	Cancer
β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD ⁺ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .

HY-176237

Nampt-IN-16	NAMPT Apoptosis	Cancer
Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC₅₀ of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD ⁺ and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .

HY-176284

OXPHOS-IN-2	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) AMPK Keap1-Nrf2	Cancer
OXPHOS-IN-2 is an orally active OXPHOS inhibitor. OXPHOS-IN-2 exhibits potent inhibitory activity in PC9 (IC₅₀ = 12.3 nM) and Bxpc-3 cells (IC₅₀ = 250 nM in glucose medium, IC₅₀ = 17.5 nM in galactose medium). OXPHOS-IN-2 decreases the *NADH/NAD* ⁺** ratio and reduces ATP levels. OXPHOS-IN-2 induces tumor cells apoptosis by activating reactive oxygen species (ROS) and downregulating the level of Nrf2. OXPHOS-IN-2 can be used for research on cancer such as non-small cell lung cancer and pancreatic cancer .

HY-B0150R

Nicotinamide (Standard) Maximum Cited Publications 78 Publications Verification Niacinamide(Standard); Nicotinic acid amide (Standard)	Reference Standards Endogenous Metabolite Sirtuin	Cancer
Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-B0150S3

Nicotinamide-d3 Niacinamide-d₃; Nicotinic acid amide-d₃	Isotope-Labeled Compounds Endogenous Metabolite Organoid Sirtuin HBV	Cancer
Nicotinamide-d₃ (Niacinamide-d₃) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-173276

SARM1-IN-4	Toll-like Receptor (TLR)	Neurological Disease
SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the *NAD+* hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).

HY-W722277A

LCC-12 formate	Interleukin Related NADH Dehydrogenase TNF Receptor JAK STAT IRAK	Inflammation/Immunology
LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to *NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α* levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .

Cat. No.	Product Name	Category	Target	Chemical Structure